Trastuzumab Deruxtecan Show Maintenance of Overall Health Status and Quality of Life in Patients with HER2 Positive Metastatic Breast Cancers
DESTINY-Brest03 was a prospective randomized phase 3 clinical trial that aimed to compare the efficacy of trastuzumab deruxtecan (T-DXd) with that of trastuzumab emtansine (T-DM1) in patients suffering from HER2 positive metastatic breast cancers.
Relateret indhold
Brænder du for at skrive?
Vil du gerne dele din forskning eller dine kliniske erfaringer med dine kollegaer inden for netop dit speciale? Har du en ide til en artikel, som du gerne vil udgive hos os? Send redaktionen en mail på redaktion@bpno.dk
Send mail til redaktionen